June 18, 2012 (Miami Beach, Florida) — In patients with newly diagnosed metastatic breast cancer, 18 F-fluoroestradiol (FES) positron emission tomography (PET) imaging is a noninvasive measure of ...

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline for estrogen receptor ...

The aim of this study was to evaluate the effect on the number of performed biopsies and costs associated with implementing positron emission tomography (PET) and computed tomography (PET/CT) with 16α ...

New research demonstrates a promising role for 18 F-Fluoroestradiol (FES)-PET imaging in diagnosis and treatment predictions for metastatic lobular breast cancer. Research presented at the San Antonio ...

Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2 and prediction of relative endocrine benefit from tamoxifen and anastrozole in HR+ breast cancer: A TransATAC study. Breast ...

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline for estrogen receptor ...

A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for breast cancer patients when diagnostic dilemmas arise. The 18 F-FES PET scan - approved by the U.S.

GE HealthCare Pharmaco-Economic Study Demonstrates Adding Breast Oncology PET Tracer to Standard Workup of Patients with Metastatic or Recurrent Breast Cancer May Yield Beneficial Clinical and ...

Reston, VA — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline for estrogen ...

Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC). Background: It can be problematic to elucidate the nature of a new lesion or complaint with standard ...

Changes in 18 F-fluorodeoxyglucose (FDG) uptake measured using PET have shown considerable promise in evaluating the early response of different types of cancer to therapies. Now, a study involving ...

A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for breast cancer patients when diagnostic dilemmas arise. The 18 F-FES PET scan—approved by the U.S.